Molina Healthcare (MOH)
(Delayed Data from NYSE)
$306.00 USD
-3.30 (-1.07%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $306.03 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$306.00 USD
-3.30 (-1.07%)
Updated Nov 14, 2024 04:00 PM ET
After-Market: $306.03 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Zacks News
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.
Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
ResMed (RMD) Q3 Earnings Miss Estimates, Margins Decline
by Zacks Equity Research
Strong demand for sleep and respiratory care devices contributed to ResMed's (RMD) fiscal third-quarter sales performance.
Community Health (CYH) Q1 Earnings Beat, Trims '22 EPS View
by Zacks Equity Research
Community Health's (CYH) first-quarter results benefit on the back of higher adjusted admissions and reduced interest expense. A lowered 2022 outlook for EPS might be a concern for investors.
Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.
Molina (MOH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 3.38% and 3.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Humana (HUM) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has Molina Healthcare (MOH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Molina (MOH) and UnitedHealth Group (UNH) have performed compared to their sector so far this year.
Molina Healthcare (MOH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Molina Healthcare's (MOH) first-quarter results are likely to reflect the benefits of increased membership in the Medicare program.
Molina (MOH) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Molina (MOH) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Should Vanguard S&P MidCap 400 ETF (IVOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVOO
Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?
by Zacks Equity Research
Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).
Molina (MOH) Up 3.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Centene (CNC) Wins Contract to Serve Medicaid Members in Indiana
by Zacks Equity Research
Centene's (CNC) Indiana subsidiary receives a contract from the Indiana Department of Administration, thereby continuing to serve the unique health needs of Indiana communities.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should iShares Core S&P MidCap ETF (IJH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJH
Here's How Much You'd Have If You Invested $1000 in Molina a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDY
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Molina (MOH) to Join S&P 500 Driven by Medicare Performance
by Zacks Equity Research
Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.
Integra's (IART) Q4 Earnings Top Estimates, Gross Margin Drops
by Zacks Equity Research
Integra (IART) records strong recovery in order demand in Q4 on broad-based strength in Neurosurgery and sales from the company's new CereLink ICP monitoring.